ClinicalTrials.gg
CompletedNCT07833124Updated Sep 22, 2026

Multiphase CT Deep Learning for Bosniak II-III Renal Cysts

An observational study in Renal Cyst, sponsored by Shanghai Zhongshan Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Shanghai Zhongshan Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
223
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This retrospective study combine radiomics and deep learning models to predict malignancy in Bosniak II-III cystic renal masses, aiming for improving preoperative risk assessment and reducing unnecessary surgery for benign lesions and avoiding delayed treatment of malignant disease.

The main question it aims to answer is:

  • How to specially predict malignancy in Bosniak II-III cystic renal masses? The investigators retrospectively included patients diagnosed with Bosniak II-III cystic renal masses based on preoperative contrast-enhanced CT.
Read the detailed description

Patients diagnosed with Bosniak II-III cystic renal masses based on preoperative contrast-enhanced CT were included. The exclusion criteria were solid portion > 25%, polycystic kidney disease, maximum diameter\<1cm, Von Hippel-Lindau syndrome, without complete CT examination or histopathology-proven CRMs, poor image quality and Bosniak I and Bosniak IV masses. Deep learning models were developed to classify renal cystic lesions as benign or malignant using multiphase CT images. The performance measure were the area under the receiver operating characteristic curve, sensitivity, specificity, and balanced accuracy.

02

Conditions studied

  • Renal Cyst

Keywords

  • Convolutional Neural Networks
  • Deep Learning
  • Tomography, X-Ray Computed
  • Kidney Diseases, Cystic
03

In context

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 652 studies on the registry; 291 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients diagnosed with renal cyst in the participated centers. Clinical and imaging data were retrospectively collected from medical records, including demographic characteristics (age, gender, BMI), cyst characters(size, loction, aterality, number of septa, septal thickness, wall thickness, presence of calcification, enhancement pattern, mural nodules, and Bosniak classification). Histopathological findings were also collected when available and were used as the reference standard for lesions that underwent surgical resection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with cystic renal masses

Exclusion criteria

Exclusion Criteria:

  • olid portion > 25%;
  • polycystic kidney disease;
  • maximum diameter\<1cm;
  • Von Hippel-Lindau syndrome;
  • without complete CT examination or histopathology-proven CRMs;
  • poor image quality;
  • Bosniak I and Bosniak IV masses.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
223 participants (actual)
Patient registry
No

Groups and cohorts

  • Benign

    Patients who were istopathologically diagnosed benign renal cysts

  • Malignant

    Patients who were istopathologically diagnosed malignant renal cysts

06

What researchers measure

Primary outcomes

  1. the area under the receiver operating characteristic curve

    The area under the receiver operating characteristic curve measures the overall ability of a binary classifier to distinguish between positive and negative classes, with values ranging from 0.5 (random guessing) to 1.0 (perfect classification).

    Time frame: preoperatively

Secondary outcomes

  1. sensitivity

    Sensitivity measures the proportion of actual positive cases that are correctly identified by the model. A higher sensitivity indicates that the model is better at detecting positive cases and produces fewer false negatives.

    Time frame: preoperatively

  2. specificity

    Specificity measures the proportion of actual negative cases that are correctly identified by the model. A higher specificity indicates that the model is better at correctly excluding negative cases and produces fewer false positives.

    Time frame: preoperatively

  3. balanced accuracy

    Balanced accuracy is the average of sensitivity and specificity. It provides an overall measure of classification performance while giving equal importance to the positive and negative classes, making it particularly useful when the classes are imbalanced.

    Time frame: preoperatively

07

Study locations

1 site
  • Zhongshan Hospital Fudan University, Location: 180th Fenglin Road, Xuhui District, Shanghai, China
    Shanghai, Shanghai Municipality 200030, China
08

References and documents

Individual participant data

Plan to share: Yes — Clinical data and extracted radiomics feature data, excluding patient information.

Supporting information: Study protocol

Time frame: Within six months after publication in the journal.

Access criteria: The data supporting this study are available from the enrolled institutions, but restrictions apply to their availability due to privacy reasons. Data can be accessed upon reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Dec 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 22, 2026
StartActual
Sep 10, 2024
Primary completionActual
Dec 28, 2024
CompletionActual
Aug 31, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07833124
Collaborators
Xuhui Central Hospital, Shanghai, Fudan University
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Sep 10, 2024
Primary completion
Dec 28, 2024
Completion
Aug 31, 2026
Last update
Sep 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion